Street Poller Media and The Boom of the Street Interview Ad Industry 
Nvidia Options Price in $280 Billion Earnings Swing 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Amazon Secures 200 MW Wind Power Deals in Sweden 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Toyota Global Sales Fall as China Demand Slumps 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Add as a preferred source on Google
WALTHAM, Mass., April 18, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA, April 21-27.
The poster is titled: “Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy”, which can be viewed here: Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy.
The purpose of this study was to assess the accuracy of the sleep monitoring technology in the Quell® device by comparison to gold standard polysomnography. The study was conducted in collaboration with Dr. John Winkelman of the Massachusetts General Hospital, Boston, MA.
"Most people with chronic pain have deficient sleep. Quell monitors the user’s sleep to provide objective feedback on this important outcome and to automatically adjust stimulation to optimize comfort and pain relief. This study evaluated the accuracy of the monitoring technology in patients with sleep disorders,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “We are pleased with the results and have identified several opportunities for improvement.”
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select
retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
[email protected]
